- GlaxoSmithKline (NYSE:GSK), in partnership with Medicines for Malaria Venture (MMV), submits a regulatory application to the Australian Therapeutics Good Administration (TGA) seeking approval of single-dose tafenoquine treatment for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria.
- If approved, tafenoquine would be the first new medicine for the prevention of relapse of P. vivax malaria in more than 60 years.
- GSK plans to progress regulatory filings in other countries in 2018.
- Shares are up a fraction on light volume.